In March 2024, the FDA approved Wegovy to cut the risk of major cardiovascular events (heart attack, stroke, and cardiovascular death) in people with heart disease and a BMI of 27 or higher
Concomitant therapy: CDEC discussed that the effectiveness of semaglutide 2.4 mg was demonstrated when combined with lifestyle and behavioural changes, which is how it was administered in the SELECT trial (i.e., individualized healthy lifestyle counselling, including diet and physical activity, was offered at every study visit)
This means even if your habits remain the same, you might see changes in your cognition, mood, energy, immunity, body composition, and more
Whether you're a foodie or just looking to satisfy your hunger, there's something for everyone
Contact us today to schedule your consultation at GoldyZ, Multan
Die Tageshchstmenge von 2 Portionen sollte nicht berschritten werden